化学蛋白质学在基因定义的癌症中发现可用药物的脆弱性
Liron Bar-Peled1, Esther K Kemper1, Radu M Suciu1
1The Skaggs Institute for Chemical Biology and Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
研究人员确定NR0B1是KEAP1突变非小细胞肺癌 (NSCLC) 的新点. 针对NR0B1的小分子破坏癌细胞生长,为这些肺癌提供了潜在的新疗法.
科学领域:
- 癌症学
- 分子生物学
- 生物化学
背景情况:
- 核红素因子2 (NRF2) 是细胞抗氧化反应的关键调节者.
- 在非小细胞肺癌 (NSCLC) 中,经常通过KEAP1突变激活NRF2.
- 直接准NRF2是很困难的,但它的异常激活会在癌细胞中产生脆弱性.
研究的目的:
- 在KEAP1突变NSCLC细胞中选择性表达的可药物向蛋白.
- 研究确定的点在支持癌细胞存活和增殖中的作用.
- 开发能够抑制这些新目标的小分子.
主要方法:
- 化学蛋白质学被用于选择性地表达KEAP1突变NSCLC细胞中的蛋白质.
- 确定NR0B1是多重复合调节基因表达的关键蛋白.
- 小分子被设计为共价地向NR0B1中的囊残留物,破坏其功能.
主要成果:
- 在KEAP1突变NSCLC中,NR0B1被确定为一种非典型的孤儿核受体.
- NR0B1形成了一个对这些癌细胞的转录输出至关重要的多重复合体.
- 针对NR0B1的小分子成功地破坏了其复合体,并抑制了KEAP1突变NSCLC细胞的独立增长.
结论:
- 在NRF2依赖的肺癌中发挥关键作用的可药物转录调节剂.
- 针对NR0B1代表了具有KEAP1突变的NSCLC的一个有前途的治疗策略.
- 这项研究强调了化学蛋白质学在发现新癌点和治疗干预的潜力.
更多相关视频
10:37Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
Published on: November 15, 2017
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
Drug Discovery: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
